Search NASA⌕ Search

SEARCH · Search NASA

Results for “Risk Assesment”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

End-To-End Risk Assesment: From Genes and Protein to Acceptable Radiation Risks for Mars Exploration

The human exploration of Mars will impose unavoidable health risks from galactic cosmic rays (GCR) and possibly solar particle events (SPE). It is the goal of NASA's Space Radiation Health Program to develop the capability to predict health risks with significant accuracy to ensure that risks are well below acceptable levels and to allow for mitigation approaches to be effective at reasonable costs. End-to-End risk assessment is the approach being followed to understand proton and heavy ion damage at the molecular, cellular, and tissue levels in order to predict the probability of the major health risk including cancer, neurological disorders, hereditary effects, cataracts, and acute radiation sickness and to develop countermeasures for mitigating risks.

Cucinotta, Francis A.↗

Personalized Risk Assesment for Adverse Drug Reactions and Treatment Failures

As NASA and other space agencies prepare for future long-term space missions beyond the LEO, the cumulative impact of risk factors encountered in space increases substantially rising concerns about astronauts health. Application of on-board medications to mitigate clinical symptoms associated with certain medical conditions and illnesses is the first line of response to ensure sustainable health and performance of crew. Unfortunately, very limited research has been conducted to determine efficacy of the earth-based pharmaceuticals in a microgravity environment. In some instances, orally administered medications taken during flight were reported to be less effective than expected. Evaluation of series of experiments involving astronauts from shuttle flights shows notable individual variability to several pharmaceuticals during flight. These data provide reasonable assumption of perturbation in CYP450 enzymes during spaceflight, which contribute to the hepatic metabolism of the majority of drugs and therefore may have significant effects on therapeutic efficacy and increase treatment-related toxicity. The genes encoding the CYP450 enzymes are highly variable in humans. Inheritable variations of CYP450 hepatic metabolizer enzymes and transport proteins play a crucial role in the inter-individual variability of drug efficiency and risks of adverse drug reactions. Additionally, there are some reports that document changes in the levels of production of drug-metabolizing enzymes in microgravity. Therefore, in order to provide a safe and effective pharmaceutical treatment in space, medications selection should be based not only on the specific efficacy of medications but also on the individual drug sensitivity and flight-induced changes in metabolism of astronauts chosen for a particular mission. To our knowledge, there was no pre-flight drug sensitivity testing on a genetic level for any of the previous manned NASA space missions. Therefore, technologies capable of predicting and managing medication efficacy, side effects, and toxicity of drugs based on individual genetic variability of crew members are increasingly needed. In this report, we present results of testing the market available Personalized Prescribing System (PPS), a comprehensive, non-invasive solution for safer, targeted medication management for every crew member. Statistical accuracy and simplicity of non-invasive sample analysis demonstrate the feasibility of drug sensitivity assessment and record-keeping tool for flight surgeons and astronauts in applying the recommended medications for situations arising in flight. The information on individual drug sensitivity will translate into personalized risk assessment for adverse drug reactions and treatment failures for each drug from the medication kit as well as predefined outcome. This will address the HHC’s raised “Concern of Clinically Relevant Unpredicted Effects of Medication” as recently updated.

medications↗

Exploring the Effectiveness of Maneuvering Guidelines for Space Traffic Management

The number of objects in space has been increasing rapidly, and the risk of collision has grown as well. Many spacecraft operators are now receiving multiple collision warnings a day. Despite this, systems to manage space traffic have been limited: there are no broadly agreed upon guidelines or rules governing the response to predicted potential collisions. Instead, spacecraft operators generally determine whether, when, and how to respond to these warnings on a manual and ad hoc basis. Coordination between operators, if it occurs, often requires repeated communication and negotiation. Some space actors have suggested that the space community should develop right of way rules, similar to those in the ground, sea, and air domains, to guide collision response decisions. However, it is unclear whether such rules would be effective, and it’s unknown whether such rules would have an equitable impact across various spacecraft operators. To address these issues, we developed the Virtual Environment for Space Traffic Analysis (VESTA), a software tool that was used to simulate the space environment with a recent catalog of objects obtained from the U.S. Space-Track.org system. We implemented multiple potential right of way rules within this model. The analysis confirmed that the choice of right of way rule makes a meaningful difference in terms of both efficiency and distributional effects in terms of collision avoidance maneuvers. For example, our analysis shows that rules in which the less massive satellite is required to maneuver results in a more equitable distribution of maneuver responsibility among space actors and also requires less fuel mass, compared to a rule in which the more massive satellite maneuvers.

space traffic management↗